Head and neck cancer is a challenging disease that is expected to account for greater than
500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy …

Throughout the last 2 decades, great strides have been made in managing patients with
locally advanced head and neck squamous cell carcinoma. In many clinical settings, they …

Single agent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have
demonstrated reproducible response rates of 5–15% in treatment of squamous cell …

Reduced nutritional state is associated with unfavourable outcomes and a lower quality of
life in patients with malignancies. Patients with active tumour disease frequently have …

Background. Reirradiation of locoregionally recurrent, previously irradiated head/neck
cancer may be considered in situations of unresectability, medical inoperability, or adverse …

Squamous cell carcinoma of the head and neck is a major health problem, and much effort
is being made in the different settings of its presentation. Much of the recent progress has …

Objective Prognosis in patients with recurrent or metastatic squamous cell carcinoma of the
head and neck is poor, and systemic chemotherapy has an only modest impact on the …

El tratamiento quirúrgico del cáncer de laringe e hipofaringe localmente avanzado implica,
en muchas ocasiones, la realización de una laringectomía total, procedimiento que implica …

Rationale: Platinum-based treatment is the standard of care for patients having Head and
Neck Cancer (HNC). Many combination regimens were investigated adding Taxane or 5-FU …